CancerVAX today reported that the Company’s CEO, Ryan Davies, recently discussed the importance of developing new drugs and medical devices and their impact on the world of healthcare with biotech entrepreneur and venture capitalist Dinesh Patel.
LEHI, Utah, May 17, 2023 (GLOBE NEWSWIRE) -- CancerVAX, developer of a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer, today reported that the Company’s CEO, Ryan Davies, recently discussed the importance of developing new drugs and medical devices and their impact on the world of healthcare with biotech entrepreneur and venture capitalist Dinesh Patel.
Dr. Patel founded TheraTech, a biotech company he took public and later sold to Watson Pharmaceuticals (now Abbvie). He then founded Salus Therapeutics, a biotech company focused on nucleic acid-based therapeutics, including gene therapy drugs and also founded Ashni Natraceuticals. Dr. Patel is the Chairman of the Utah Science Technology and Research Initiative (USTAR). He also serves as Executive Chairman of Xenocor and Chairman of the Board of Light Line Medical (both medical device companies) and is the co-founder and board member of New Eyes.
Beyond his extensive career in the biotech space, Dr. Patel is also an active philanthropist actively helping many worthy organizations in the United States. Dr. Patel sits on the board of The Leonardo (a prestigious museum in Salt Lake City) and is a member of the board of the Utah Symphony & Opera. Dr. Patel was a founding partner of v-Spring Capital, a Utah-based venture capital firm active in biotech and high-tech sectors. Dr. Patel also continues to invest on a personal level through Patel Family Investments.
“It was a delight speaking with Dinseh. I’ve known and admired him as an investor and biotech entrepreneur for many years,” said Ryan Davies, CancerVAX CEO. “His contributions to the world of medicine and healthcare are remarkable.”
The Podcast can be viewed at: https://youtu.be/Um1Ca045Beg
For more information about CancerVAX, please visit http:///www.cancervax.com/.
About Us
CancerVAX, Inc. is a pre-clinical biotechnology company developing a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer. Working with a team of experienced cancer researchers and physicians at UCLA, we intend to create a Universal Cancer Vaccine that will detect, mark, and destroy only the diseased cells with an incredibly high level of precision. Much like the COVID-19 vaccines that train the body to recognize and destroy the coronavirus, our cancer vaccine will leverage the body’s own immune system to destroy cancer cells. As we develop our universal cancer vaccine, we are also working with UCLA to develop single-disease cancer treatments targeting Ewing sarcoma, a rare but deadly bone and soft tissue cancer that primarily affects children and young adults. We look forward to the day when treating cancer will be as simple as getting a flu shot.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Press Contact:
CancerVAX, Inc.
Tel: (805) 356-1810
info@CancerVAX.com
